TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female and male patients from 18-75 years~2. A history of symptoms of bladder pain/discomfort described as suprapubic pain related to bladder filling, accompanied by other symptoms such as daytime and/or nighttime frequency in the absence of infection or other pathology, with or without the typical cystoscopic findings of interstitial cystitis~3. Patients willing and able to complete the necessary questionnaires~Exclusion Criteria:~1. Patients with transitional cell carcinoma of the bladder or other significant malignancy~2. Pregnant women~3. Breastfeading women~4. Patients with significant bacteriuria~5. Patients with hematuria~6. Neurogenic bladder~7. Patients with indwelling catheters~8. Chronic bacterial prostatitis~9. Currently receiving or having received investigational drugs thirty (30) days or less prior to screening~10. Currently receiving or having had prior therapy with intravesical treatment (eg. Uracyst, Cystistat®, heparin or BCG)~11. Receiving therapy for less than three months with antidepressants, antihistaminics, hormonal agonists or antagonists; hence patient not stabilized on therapy. (Stable therapy defined as continuous treatment for at least three months.)~12. IC symptoms relieved by antimicrobials, anticholinergics or antispasmodics~13. Functional Bladder capacity of greater than 400 ml~14. Neurologic disease affecting bladder function; any previous surgery or procedure having affected bladder function~15. Current diagnosis of chemical, tuberculous or radiation cystitis~16. bladder or lower ureteral calculi~17. History of cancer within the last five years other than adequately treated non-melanoma skin cancers~18. Active sexual transmitted disease~19. Current vaginitis~20. Endometriosis~21. Any condition/disease which in the opinion of the investigator could interfere with patient compliance and/ or interfere with the interpretation of the treatment results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Chondroitin sulphate 2% (Type: EXPERIMENTAL): chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
- DMSO 50% (Type: ACTIVE_COMPARATOR): DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Current cigarette smoker~* Averages at least 10 cigarettes/day for 5 or more years~* DSM-IV diagnosis of Nicotine Dependence~* Breath carbon monoxide \> 6 ppm~* Motivated to quit: score \> 8 on Contemplation Ladder~* Age \> 18 years~Exclusion Criteria:~* Current illicit substance use~* Other tobacco use (e.g., cigar, pipe)~* History of psychosis~* Past or current cardiovascular disease~* Impaired renal functioning~* Pregnancy~* Nursing~* Current treatment for smoking cessation~* Clinically significant depressive symptoms (CES-D \> 16)~* Current suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Scheduled Gradual Reduction + Varenicline (Type: EXPERIMENTAL): Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
- Scheduled Gradual Reduction + Placebo Drug (Type: EXPERIMENTAL): Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
- Basic Advice + Varenicline (Type: EXPERIMENTAL): Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
- Basic Advice + Placebo Drug (Type: PLACEBO_COMPARATOR): Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject satisfied Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for a primary diagnosis of Bipolar Disorder, most recently manic~* The patient is willing to be hospitalized on an inpatient psychiatric unit for a minimum of seven (7) days.~* Subject has been treated with lithium in the past.~* Subject has been treated with divalproex or carbamazepine in the past.~* Subject has been treated with Haldol or haloperidol in the past.~Exclusion Criteria:~* Subjects lacks the capacity to provide informed consent~* Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators~* Subject has been dependent on a drug (other than nicotine or caffeine) in the last three (3) months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of TPD Heat Lamp for Tennis Elbow Pain - a Randomized-controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that have consented.~* Patients diagnosed with tennis elbow pain. Definition of tennis elbow (lateral epicondylitis) is pain or tenderness on loading relevant muscle on the lateral epicondyle, with no shoulder or wrist pain.. Patients recruited will be interviewed and examined to confirm the clinical diagnosis. The level of pain will be assessed with the visual analogue scale (VAS) and level of functional disability with the QUICKDASH Questionnaire.~* Patients must be between the ages of 18-65.~Exclusion Criteria:~* Patients with existing diagnosis of neuropathic pain, metabolic or metastatic bone pain will be excluded. So will patients with recent or previous bone fracture of the elbow and epicondyles.~* Patients taking any form of oral analgesia in the last 2 weeks prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
- 2 (Type: OTHER): Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraosseous Infusion of Unrelated Cord Blood Grafts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 36 months to 60 years old (YO)~2. No prior autologous or allogeneic transplant~3. Karnofsky performance score or Lansky Play-Performance of at least 80~Exclusion Criteria:~1. Age \< 36 months or \> 60 YO~2. creatinine clearance or nuclear medicine GFR of \< 50 mL/min~3. cardiac ejection fraction \< 50%~4. bilirubin \> 2 × upper limit of normal or ALT \> 4 × upper limit of normal or unresolved veno-occlusive disease~5. Pulmonary carbon monoxide diffusing capacity (DLCO), adjusted for Hgb \< 50%~6. Karnofsky performance score or Lansky Play-Performance Scale \<80~7. Uncontrolled viral, bacterial, or fungal infection at the time of study enrollment~8. Seropositive for HIV~9. Availability of a willing and well HLA matched related (genotypically identical or mismatched at a single allele or antigen defined by typing at HLA A, B, C and DRB1 loci) donor~10. Availability of a willing and well HLA matched unrelated (allele matched or mismatched at a single allele defined by allele level typing for HLA A, B, C and DRB1 loci) adult blood or marrow donor~11. Availability of an umbilical cord blood unit, which provides at least a 4/6 HLA match as defined above and ≥ 5.0 \* 107 NC/Kg (cryopreserved)

- Gender: ALL
- Minimum Age: 36 Months
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* presence of sinus rhythm on the screening electrocardiogram~* first-time elective open heart surgery~Exclusion Criteria:~* absence of sinus rhythm at screening~* known allergy or intolerance to gluten or anthocyanin compound~* regularly consuming of anthocyanin or antioxidant supplements,~* being currently pregnant,~* existing or planned cardiac transplant or use of ventricular assist device,~* being unable or unwilling to provide informed consent,~* history of hepatic or renal disease,~* history of cancer history of substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Soluble corn flour not rich in anthocyanins
- High-anthocyanin rich corn flour (Type: ACTIVE_COMPARATOR): Soluble corn flour at high content in anthocyanins

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of the Inflammatory/ Pathogen Burden for Cardiac Ageing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 60-75~* physical activity less than 3 times a week~* written informed consent~Exclusion Criteria:~* heart disease requiring treatment~* treatment with beta-receptor-antagonists~* treatment with statins~* treatment with immunosuppressive drugs~* treatment with anti- inflammatory drugs~* underlying hematological disease~* alcohol abuse, drug abuse~* diabetes mellitus~* study participation within past 30 days~* known intolerance to active agent or any other component of the drug~* active liver disease or unexplained persistent elevation of serum levels of transaminases or cholestasis~* existing myopathy~* pregnancy or nursing period~* absence of an ophthalmological examination within 12 month prior inclusion~* known cataract

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- statins, standardised physical training (Type: ACTIVE_COMPARATOR): None
- to continue with current lifestyle (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between the Fastrach and CTrach Laryngeal Mask Airway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with an ASA score of 1-3.~2. Scheduled for elective surgical procedure~3. Age 18 and above~4. Patients with Mallampati airway classification scores III and IV~Exclusion Criteria:~1. Current pregnancy~2. Patients undergoing brain aneurysm clipping brain arteriovenous malformation surgery or vascular surgery procedures~3. Patients with obstructive sleep apnea or with a history of difficult ventilation~4. Mouth opening less than 3 cm.~5. Patients with indication for awake fiberoptic intubation or with a history of difficult intubation~6. Patients with cancer of the neck or the upper airway~7. Emergent surgery, patients requiring rapid sequence induction~8. Patients with severe gastroesophageal reflux~9. Patients with severe cardiac, pulmonary, hepatic or renal co-morbidities. 10. Patients unable to consent their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Fastrach Laryngeal Mask Airway intubation
- Group 2 (Type: ACTIVE_COMPARATOR): Intubation of difficult airway using CTrach Laryngeal Mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sickle Cell Trait and the Risk of Venous Thromboembolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Peripartum women (White, Black) with Hemoglobin AA or AS~Exclusion Criteria:~* Hispanic ethnicity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- White women with Hb AA (Type: None): White pregnant and postpartum women with Hb AA
- Black women with Hb AA (Type: None): Black pregnant and postpartum women with HbAA
- Black women with Sickle Trait (Type: None): Black pregnant and postpartum women with HbAS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes type 2 (HbA1c =\>7%)~* Generalized moderate to severe chronic periodontitis.~* Minimum of 10 permanent teeth~* Registered LLU patients~Exclusion Criteria:~* Well controlled Diabetes type 2~* Other systematic conditions with known associations to periodontitis~* Intra-oral conditions which may interfere with the accuracy of periodontal probing~* BMI greater than 45%

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CWC with HBO (Type: OTHER): Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
- CWC without HBO (Type: OTHER): Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer~  * Medically inoperable stage I or II disease~ * Stage III disease eligible provided the following are true:~    * No supraclavicular node involvement~   * No peripherally located lower lobe tumor AND contralateral upper mediastinal node involvement~* No distant metastasis~* No malignant pleural or pericardial effusion~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Cardiovascular~* No prior myocardial infarction~* No prior complete bundle branch block~* No other prior cardiovascular disease resulting in New York Heart Association class III or IV heart disease~* No clinically significant cardiac arrhythmias~* No congestive heart failure~Pulmonary~* FEV_1 at least 1.2 L OR~* DLCO at least 60%~Other~* No other prior or concurrent malignancy except cured basal cell skin cancer or carcinoma in situ of the cervix~* No intractable or uncontrolled infection~* No psychological, familial, social, or geographical condition that would preclude study compliance and follow-up~* Able to tolerate a course of radiotherapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 3 weeks since prior chemotherapy~* No prior anthracyclines~* No concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy to the chest area~Surgery~* No prior therapeutic surgery to the chest area~Other~* No other prior therapy to the chest area

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Oxytocin Alter Tolerance to or Motivation for Alcohol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heavy alcohol drinkers.~* Able to understand/complete questionnaires and procedures in English.~* Have venous access sufficient to allow blood sampling.~Exclusion Criteria:~* Latex allergy.~* Nasal condition that compromises delivery and/or absorption of intra-nasal oxytocin~* Pregnant or breast-feeding women.~* Desire to be treated for any substance use disorder or court ordered to not drink alcohol~* Medical disorders or other conditions such as alcohol withdrawal seizures or delirium tremens that may influence study outcome or participant safety.~* Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the PI to adversely affect participant safety or data integrity.~* Medications (past 30 days) that could influence participant safety or data integrity (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by the PI.~* DSM 5 Disorders (other than alcohol) or current/history of neurological disease of cerebral origin, or head injury with \> 20 min loss of consciousness, if determined by the PI to affect participant safety or data integrity.~* Positive breath alcohol reading at beginning of the experimental session.~* Actively suicidal (for example, any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the PI.~* Any condition for which the PI and investigative team determine it is unsafe or not prudent to enroll a participant.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Clamp (Type: EXPERIMENTAL): Clamped alcohol exposure, repeated tests of subjective and cognitive effects of alcohol, 2 sessions (intranasal oxytocin or placebo), double blind
- Progressive work for alcohol (Type: EXPERIMENTAL): Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Outcome of Chinese Women With Genitourinary Syndrome of Menopause Treated With Vaginal Dehydroepiandrosterone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~• All menopause Chinese women who have moderate to severe symptoms of Genitourinary syndrome of menopause (GSM) and treated with vaginal DHEA~Exclusion Criteria:~* Genitourinary syndrome of menopause (GSM) due to other differential diagnosis such as candidiasis / lichen sclerosis/urodynamic stress incontinence/ detrusor over-activity.~* Amenorrhoea due to medication~* History of hormonal sensitive cancer, active or history of thromboembolic events, unexplained abnormal uterine bleeding~* Endometrial thickness ≥ 5mm

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Chinese women with moderate to severe symptoms of genitourinary syndrome of menopause (Type: None): It is a single-group study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy